Press Releases

Posted on August 4, 2010 | Posted in Press Releases

BrainCells Inc. Acquires Clinical -Stage Compound Sabcomeline From Proximagen Group

Posted on June 14, 2010 | Posted in Press Releases

BrainCells Inc. Announces Results From Exploratory Phase 2a Trial of BCI-540 in Depression With Anxiety

Posted on April 29, 2010 | Posted in Press Releases

BrainCells Issued First U.S. Patent For Drug Combinations That Modulate Neurogenesis

Posted on November 9, 2009 | Posted in Press Releases

BrainCells’ BCI-540 Investigational Treatment for Depression With Anxiety Named One of Top 10 Most Interesting Neuroscience Projects

Posted on October 20, 2009 | Posted in Press Releases

BrainCells Inc. Broadens Scientific Advisory Board Adding Drs. Edward Scolnick and David Holtzman

Posted on July 27, 2009 | Posted in Press Releases

Unlikely Treatment Identified by BrainCells Neurogenesis Platform Improved Clinical Outcomes in Patients Suffering from Depression

Posted on March 30, 2009 | Posted in Press Releases

BrainCells Inc. Appoints Philip Jochelson, M.D. Chief Medical Officer
and Jason Levin Chief Business Officer

Posted on March 18, 2009 | Posted in Press Releases

BrainCells Inc. Selected to Present at InsideVenture’s Debut Investor Conference March 25-26, Santa Barbara, California

Posted on December 2, 2008 | Posted in Press Releases

BrainCells Inc. Appoints David E. Thompson to its Board of Directors

Posted on November 4, 2008 | Posted in Press Releases

BrainCells’ Neurogenic Treatments for Depression Named a Top Unpartnered Project by Windhover in the Area of Neuroscience